Alcon's Late-Stage Pipeline Set To Drive Revenue Growth Next Year -- Market Talk

Dow Jones

2024-12-17

1505 GMT - Alcon's pipeline of products in the late stage of development is the most solid since its spinoff from Swiss pharma giant Novartis, and is set to drive revenue growth next year, Needham analysts say. The Swiss-American medical device company has eight planned product launches in 2025, the analyst write in a note. Among them, contact lenses PanOptix Pro and Precision 7 will be watched keenly by investors, they say. Alcon's current valuation, significantly below historical averages, presents an attractive entry point. Commercial investment risks and foreign currency headwinds are already factored in, they add. Alcon shares rise 0.34% to 75.86 Swiss francs. (helena.smolak@wsj.com)

(END) Dow Jones Newswires

December 17, 2024 10:05 ET (15:05 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2492966450"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492966450\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2492966450?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-17 23:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492966450","market":"other","top_or_hot":-1,"title":"Alcon's Late-Stage Pipeline Set To Drive Revenue Growth Next Year -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1505 GMT - Alcon's pipeline of products in the late stage of development is the most solid since its spinoff from Swiss pharma giant Novartis, and is set to drive revenue growth next year, Needham analysts say. The Swiss-American medical device company has eight planned product launches in 2025, the analyst write in a note. Among them, contact lenses PanOptix Pro and Precision 7 will be watched keenly by investors, they say. Alcon's current valuation, significantly below historical averages, presents an attractive entry point. Commercial investment risks and foreign currency headwinds are already factored in, they add. Alcon shares rise 0.34% to 75.86 Swiss francs. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 17, 2024 10:05 ET (15:05 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alcon's Late-Stage Pipeline Set To Drive Revenue Growth Next Year -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlcon's Late-Stage Pipeline Set To Drive Revenue Growth Next Year -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-12-17 23:05</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1505 GMT - Alcon's pipeline of products in the late stage of development is the most solid since its spinoff from Swiss pharma giant Novartis, and is set to drive revenue growth next year, Needham analysts say. The Swiss-American medical device company has eight planned product launches in 2025, the analyst write in a note. Among them, contact lenses PanOptix Pro and Precision 7 will be watched keenly by investors, they say. Alcon's current valuation, significantly below historical averages, presents an attractive entry point. Commercial investment risks and foreign currency headwinds are already factored in, they add. Alcon shares rise 0.34% to 75.86 Swiss francs. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 17, 2024 10:05 ET (15:05 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALC","symbol_name":"愛爾康","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492966450","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492966450","pubTimestamp":1734447900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1505 GMT - Alcon's pipeline of products in the late stage of development is the most solid since its spinoff from Swiss pharma giant Novartis, and is set to drive revenue growth next year, Needham analysts say. The Swiss-American medical device company has eight planned product launches in 2025, the analyst write in a note. Among them, contact lenses PanOptix Pro and Precision 7 will be watched keenly by investors, they say. Alcon's current valuation, significantly below historical averages, presents an attractive entry point. Commercial investment risks and foreign currency headwinds are already factored in, they add. Alcon shares rise 0.34% to 75.86 Swiss francs. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ALC":"爱尔康","SSI":"Stage Stores Inc"},"translate_title":"爱尔康的后期产品线将推动明年收入增长——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALC":0.9,"SSI":1},"content_text":"1505 GMT - Alcon's pipeline of products in the late stage of development is the most solid since its spinoff from Swiss pharma giant Novartis, and is set to drive revenue growth next year, Needham analysts say. The Swiss-American medical device company has eight planned product launches in 2025, the analyst write in a note. Among them, contact lenses PanOptix Pro and Precision 7 will be watched keenly by investors, they say. Alcon's current valuation, significantly below historical averages, presents an attractive entry point. Commercial investment risks and foreign currency headwinds are already factored in, they add. Alcon shares rise 0.34% to 75.86 Swiss francs. (helena.smolak@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2024 10:05 ET (15:05 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}